Clinical Trial Update: Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II trial of CAMPATH (alemtuzumab) in relapsed or refractory Non-Hodgkin lymphoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• CAMPATH (ALEMTUZUMAB)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Non-Hodgkins Lymphoma | Phase 1, Phase 2 | Status: TERMINATED